Table 2 Patient characteristics
Ven-Aza treated patients | Model fitting patients | Train/test patients | |
|---|---|---|---|
# Patients | 92 | 71 | 33 |
# Male | 53 (58%) | 40 (56%) | 20 (61%) |
# Age ≤75 | 61 (66%) | 47 (66%) | 22 (67%) |
# Alive | 31 (34%) | 30 (42%) | 20 (61%) |
# De Novo AML | 48 (52%) | 40 (56%) | 25 (76%) |
# Recurrent, relapse, or secondary AML | 44 (48%) | 31 (44%) | 8 (24%) |
# Achieved remission | 74 (80%) | 66 (93%) | 33 (100%) |
# Relapsing | 42 (46%) | 35 (49%) | 14 (42%) |
Median progression-free survival | 232.5 days | 329 days | 533 days |
Median overall survival | 395 days | 466 days | 585 days |
Median neutrophil measurements | 14.5 | 19 | 33 |
Median bone marrow measurements | 5 | 6 | 8 |
